Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial
- PMID: 17868802
- DOI: 10.1016/j.jacc.2007.06.015
Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial
Abstract
Objectives: We assessed the impact of vessel size on angiographic and long-term clinical outcome after percutaneous coronary intervention (PCI) with sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) within a randomized trial (SIRTAX [Sirolimus-Eluting Stent Compared With Paclitaxel-Eluting Stent for Coronary Revascularization]).
Background: Percutaneous coronary intervention in small-vessel disease is associated with an increased risk of major adverse cardiac events (MACE).
Methods: A total of 1,012 patients were randomly assigned to treatment with SES (n = 503) or PES (n = 509). A stratified analysis of angiographic and clinical outcome was performed up to 2 years after PCI according to size of the treated vessel (reference vessel diameter < or =2.75 vs. >2.75 mm).
Results: Of 1,012 patients, 370 patients (37%) with 495 lesions underwent stent implantation in small vessels only, 504 patients (50%) with 613 lesions in large vessels only, and 138 patients (14%) with 301 lesions in both small and large vessels (mixed). In patients with small-vessel stents, SES reduced MACE by 55% (10.4% vs. 21.4%; p = 0.004), mainly driven by a 69% reduction of target lesion revascularization (TLR) (6.0% vs. 17.7%; p = 0.001) compared with PES at 2 years. In patients with large- and mixed-vessel stents, rates of MACE (large: 10.4% vs. 13.1%; p = 0.33; mixed: 16.7% vs. 18.0%; p = 0.83) and TLR (large: 6.9% vs. 8.6%; p = 0.47; mixed: 16.7% vs. 15.4%; p = 0.86) were similar for SES and PES. There were no significant differences with respect to death and myocardial infarction between the 3 groups.
Conclusions: Compared with PES, SES more effectively reduced MACE and TLR in small-vessel disease. Differences between SES and PES appear less pronounced in patients with large- and mixed-vessel disease. (The SIRTAX trial; http://clinicaltrials.gov/ct/show/NCT00297661?order=1; NCT00297661).
Comment in
-
Are sirolimus-eluting stents superior to paclitaxel-eluting stents in patients with small-vessel disease?Nat Clin Pract Cardiovasc Med. 2008 Apr;5(4):188-9. doi: 10.1038/ncpcardio1120. Epub 2008 Jan 22. Nat Clin Pract Cardiovasc Med. 2008. PMID: 18212770 No abstract available.
Similar articles
-
Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.Catheter Cardiovasc Interv. 2013 Jan 1;81(1):E23-8. doi: 10.1002/ccd.24375. Epub 2012 May 4. Catheter Cardiovasc Interv. 2013. PMID: 22431239 Clinical Trial.
-
In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.JACC Cardiovasc Interv. 2009 Aug;2(8):767-75. doi: 10.1016/j.jcin.2009.05.016. JACC Cardiovasc Interv. 2009. PMID: 19695546
-
Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.JACC Cardiovasc Interv. 2011 Nov;4(11):1209-15. doi: 10.1016/j.jcin.2011.07.016. JACC Cardiovasc Interv. 2011. PMID: 22115661
-
The efficacy of sirolimus- and paclitaxel-eluting stents: a meta-analysis of randomized controlled trials.Can J Cardiol. 2005 May 15;21(7):581-7. Can J Cardiol. 2005. PMID: 15940356 Review.
-
[When are drug-eluting stents effective? A critical analysis of the presently available data].Z Kardiol. 2004 Sep;93(9):649-63. doi: 10.1007/s00392-004-0143-8. Z Kardiol. 2004. PMID: 15365732 Review. German.
Cited by
-
Three year follow-up of the sirolimus-eluting stent and the paclitaxel-eluting stent in daily practice.Clin Cardiol. 2009 Dec;32(12):E63-7. doi: 10.1002/clc.20550. Clin Cardiol. 2009. PMID: 20014187 Free PMC article.
-
The use of paclitaxel coated balloon (PCB) in acute coronary syndrome of small vessel de novo lesions: an analysis of a prospective 'real world' registry.Springerplus. 2016 Mar 25;5:373. doi: 10.1186/s40064-016-2014-y. eCollection 2016. Springerplus. 2016. PMID: 27066381 Free PMC article.
-
Associations of Culprit Vessel Size and Plaque Characteristics in Patients with ST-Segment Elevation Myocardial Infarction.Rev Cardiovasc Med. 2023 Jun 29;24(7):186. doi: 10.31083/j.rcm2407186. eCollection 2023 Jul. Rev Cardiovasc Med. 2023. PMID: 39077009 Free PMC article.
-
Vessel Size and Long-Term Outcomes After Limus-Based Drug-Eluting Stent Implantation Focusing on Medium- and Small-Diameter Vessels.Angiology. 2017 Jul;68(6):535-541. doi: 10.1177/0003319716667341. Epub 2016 Sep 11. Angiology. 2017. PMID: 27620336 Free PMC article.
-
Cardiac CT in the Emergency Department: Contrasting Evidence from Registries and Randomized Controlled Trials.Curr Cardiol Rep. 2018 Mar 8;20(4):24. doi: 10.1007/s11886-018-0965-z. Curr Cardiol Rep. 2018. PMID: 29520449 Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous